Resiquimod‐Induced Nanovaccine (RINV) for Personalized Cancer Immunotherapy
Angewandte Chemie International Edition · 18.08.2025 · 64 (34)
DOI: 10.1002/anie.202507902 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 30.06.2025. Verfasst von Wei Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Smart Nanomedicines, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510006, China. Hauptthemen laut MEDLINE: Imidazoles, Immunotherapy, Cancer Vaccines, Nanoparticles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
Cancer nanovaccines have emerged as a promising modality for cancer immunotherapy due to their capability of eliciting robust tumor‐specific immune responses. However, structural complexity and insufficient spatiotemporal coordination of immune activation pose substantial challenges for optimizing the therapeutic potential of nanovaccines. Herein, a resiquimod‐induced nanovaccine (RINV) is devised for personalized cancer immunotherapy. Toll‐like receptor (TLR) 7/8 agonist resiquimod (R848) was covalently conjugated to fifth‐generation polyamidoamine (G5‐PAMAM) dendrimer through a disulfide linker to obtain the vaccine carrier G5‐R848. In this design, R848 not only fulfills its biological role as a vaccine adjuvant but facilitates uniform nanovaccine formation with the model protein antigen ovalbumin (OVA) due to its distinctive chemical structure. Redox‐triggered intracellular R848 release further promotes cytosolic delivery of antigen and subsequent antigen cross‐presentation. In vivo studies demonstrated that the nanovaccine induces remarkable prophylactic and therapeutic effects in the B16F10‐OVA melanoma model. Moreover, G5‐R848 forms personalized nanovaccines by complexing with cell lysates from resected B16F10 and 4T1 tumor tissues, effectively inhibiting postoperative tumor recurrence and metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Smart Nanomedicines, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510006, China.
- School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 511442, China.
- State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, China.
- National Engineering Research Center for Tissue Restoration and Reconstruction, and Guangdong Provincial Key Laboratory of Biomedical Engineering, South China University of Technology, Guangzhou, 510006, China.
- The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou, 510006, China.
ORCID-Profile: Jin-Zhi Du
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Guangzhou Science and Technology Planning Project
- National Key Research and Development Program of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Xu, W., Luo, J. Q., Wang, S. Y., Gao, Z. L., Luo, F. Q., Zhang, X., Wang, K. S., Du, J., Ji, Z. L., Du, J. Z., & Wang, J. (2025). Resiquimod‐Induced Nanovaccine (RINV) for Personalized Cancer Immunotherapy. Angewandte Chemie International Edition, 64(34). https://doi.org/10.1002/anie.202507902
Vancouver
Xu W, Luo JQ, Wang SY, Gao ZL, Luo FQ, Zhang X, et al. Resiquimod‐Induced Nanovaccine (RINV) for Personalized Cancer Immunotherapy. Angewandte Chemie International Edition. 2025;64(34). doi:10.1002/anie.202507902
BibTeX
@article{Xu2025,
author = {Xu, Wei and Luo, Jia-Qi and Wang, Shi-Yu and Gao, Zhen-Lin and Luo, Feng-Qin and Zhang, Xin and Wang, Kai-Shuo and Du, Juan and Ji, Zhi-Liang and Du, Jin-Zhi and Wang, Jun},
title = {Resiquimod‐Induced Nanovaccine (RINV) for Personalized Cancer Immunotherapy},
journal = {Angewandte Chemie International Edition},
year = {2025},
volume = {64},
number = {34},
doi = {10.1002/anie.202507902}
}
EUVIMED